Results 161 to 170 of about 30,793 (265)

Targeting Neoantigens in Cancer: Possibilities and Opportunities in Breast Cancer

As one of the most prevalent forms of cancer worldwide, breast cancer has garnered significant attention within the clinical research setting. While traditional treatment employs a multidisciplinary approach including a variety of therapies such as ...
Zuhair Chaudhry, Kayvan Sasaninia, Vikrant Rai, Anik Boyadzhyan   +3 more
core   +1 more source

Metastatic Urachal Carcinoma With Microsatellite Stability and Low Tumor Mutational Burden Achieving a Durable Response to Pembrolizumab After Platinum Failure

IJU Case Reports, Volume 9, Issue 6, November 2026.
ABSTRACT Introduction Urachal carcinoma is a rare and aggressive malignancy with no established systemic therapy after platinum failure. Evidence for immune checkpoint inhibitors (ICIs) remains limited, particularly in tumors without established favorable biomarkers such as microsatellite instability‐high status or high tumor mutational burden.
Fumihiro Ito, Koki Kobayashi, Gaku Hayashi, Shunsuke Kamijo, Takashi Fujita   +4 more
wiley   +1 more source

Induced mismatch repair deficiency: a hypothesis for the transient and reversible sensitization of mismatch repair-proficient tumors to Immune checkpoint blockade. [PDF]

Front Immunol
Assumpção PP, Leal A, Barra WF, Hirata MH, Steimbach JV, Burbano RMR, Kassab P, Bencivenga M, Bonamino MH, P&D consortium.   +9 more
europepmc   +1 more source

Durable Complete Response to Pembrolizumab for Postoperative Nodal Recurrence of Lynch Syndrome–Associated Upper Tract Urothelial Carcinoma: A Case Report

IJU Case Reports, Volume 9, Issue 6, November 2026.
ABSTRACT Introduction Germline mutations in mismatch repair genes cause Lynch syndrome and are associated with upper tract urothelial carcinoma (UTUC). Tumors with deficient mismatch repair (dMMR) or microsatellite instability–high (MSI‐H) may respond favorably to immune checkpoint inhibitors.
Kaya Atagi, Shinkuro Yamamoto, Nobutaka Shimizu, Mitsuko Iguchi, Ryu Shigehisa, Tomoya Nao, Tsutomu Shimamoto, Hideo Fukuhara, Satoshi Fukata, Keiji Inoue   +9 more
wiley   +1 more source

Advances and Challenges in mRNA Cancer Vaccines: Individualized Design and Delivery. [PDF]

Bioengineering (Basel)
Huang L, Tang Y, Chen X, Wu Z, Xiao J, Xiang Q, Tian H.   +6 more
europepmc   +1 more source

The FOXQ1/SSBP2 Regulatory Axis Drives Malignant Progression of Melanoma

Molecular Carcinogenesis, Volume 65, Issue 11, Page 1459-1477, November 2026.
ABSTRACT Melanoma is a highly aggressive skin cancer with poor prognosis, often linked to excessive UV exposure. Despite advancements in immunotherapy and targeted treatments, melanoma's invasiveness and metastatic potential remain significant challenges.
Xiaoyu Zhang, Yu Hou, Jiahui Liu, Yuehua Han, Jiangang Feng   +4 more
wiley   +1 more source

Long-read sequencing reveals widespread novel splicing and neojunction-derived neoantigens in nasopharyngeal carcinoma. [PDF]

Genome Res
Shuai Y, Yao H, Wang B, Chung GTY, Wang X, Zhong M, Zhu Z, Li CS, Tsang CM, Lo KW, Wang X.   +10 more
europepmc   +1 more source

Neoantigen prediction and the need for validation [PDF]

Nature Biotechnology, 2017
Antonella, Vitiello, Maurizio, Zanetti
openaire   +2 more sources

Bispecific NK‐Cell Engager Targeting TP53 Mutation Through Integration of a TCR‐mimic Antibody

MedComm, Volume 7, Issue 11, November 2026.
Most existing NK cell engagers (NKCEs) target tumor‐associated antigens (TAAs), risking on‐target, off‐tumor toxicity. We engineered a novel NKCE termed C33×CD16, a single‐chain diabody (scDb) constructed by fusing TCR‐mimic antibody C33‐Ab (targeting p53R175H/HLA‐A*02:01) to the scFv of 3G8 (anti‐CD16 antibody) (a).
Hanfei Wu, Zhe Zhao, Li Zhang, Xuan Xiong, Mengdie Yang, Weiping Ge, Danyue Zhi, Xiaobin Cao, Chuanqian Yi, Yong Qiao, Junjun Cao, Yan Mei, Shiping Jiao, Quan Liu, Hao Zhou, Zhongjuan Xu, Guangli Suo   +16 more
wiley   +1 more source

Immune Recognition and Sculpting of Neoantigens in Human Tumors

Understanding the extent to which the immune system can recognize and sculpt human tumors is critical to designing and implementing new immunotherapeutic approaches to cancer. Immune recognition of tumors is primarily mediated through segments of mutated
Borden, Elizabeth
core   +1 more source